Caring Cross aims to establish open-source viral vector manufacturing platforms for adeno-associated virus (AAV) and lentivirus (LV).
AAV and LV can be used in a variety of contexts including for vaccines and therapeutics to prepare for and respond to coronavirus. The processes in this project will be developed from first principles and published methods, and then be iteratively developed into a complete and robust manufacturing process.
The project will involve:
Separately, the team will identify and list assays that are necessary but are best performed at a vendor site due to complexity and necessary expertise, such as sterility, adventitious virus testing, RCL, etc.
Reference standards for LV and AAV will be manufactured and characterized by Caring Cross and collaborators for release. All processes, methods, assays, materials, etc. generated in this project will be made publicly available through Caring Cross and NIIMBL.
An open platform production process for LV and AAV will be made available that can be used as a starting point for the manufacture of medicines and vaccines to respond to coronavirus.
The open platform will remove a large barrier to production and enable faster response by large and small companies and academic/non-profit organizations.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Caring Cross, Inc.